Photo: Iuliia Burmistrova / Moment / Getty Images
When patients stop taking GLP-1 weight loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, they often face significant challenges. According to BBC Future, many regain a large portion of the weight they lost. Studies show that within a year of stopping, patients can regain about two-thirds of the weight they initially lost. This weight regain is often faster than the initial weight loss and primarily consists of fat rather than muscle, which can negatively affect metabolic health.
Dr. Laura Choi, a weight-loss specialist, explains that GLP-1 drugs work by mimicking the glucagon-like peptide-1 hormone, which helps control hunger and blood sugar levels. When these drugs are stopped, hunger often returns, leading to potential weight gain. Dr. Choi notes that around 37% of lost weight is typically regained within a year of stopping the medication, though this varies among individuals. Factors like previous weight-loss cycles and lifestyle changes can influence the extent of weight regain.
The emotional impact of stopping these medications can be significant. As Legacy Community Health highlights, patients may feel defeated or ashamed as their appetite returns and weight increases. This can lead to distress or disordered eating habits. Experts recommend that patients work with healthcare providers to create a plan when considering stopping GLP-1 medications. This includes consulting doctors, dietitians, and pharmacists to ensure a supportive transition.
Despite the challenges, GLP-1 drugs have been life-changing for many, helping them achieve significant weight loss and improved health markers. However, the high cost and potential side effects can be barriers for some patients. As the use of these drugs grows, ongoing research aims to better understand their long-term effects and how to manage weight after discontinuation.